BioSpace News Archive

Coya Therapeutics, Inc. announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, will present data on its novel oxidative stress biomarker candidate from a large cohort of Amyotrophic Latera Sclerosis (ALS) patients at the upcoming Society of Neuroimmune Pharmacology Conference being held on March 10-13, 2024 in Charleston, SC.

Umoja Biopharma, Inc. today announced that the company will participate in a Fireside Chat at the Evercore ISI 2024 Emerging Biotech Conference, taking place virtually on February 28-29, 2024.

Cosette Pharmaceuticals, Inc. (“Cosette”) announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for the first generic version of RECTIV® (nitroglycerin) ointment, 0.4%, with 180 days Competitive Generic Therapy (CGT) exclusivity.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its fourth quarter and full-year 2023 financial results on Wednesday, February 28, 2024.

ARS Pharmaceuticals, Inc. today announced that it will host a virtual investor day highlighting neffy ® (epinephrine nasal spray) on Thursday, March 7, 2024, at 1:00 p.m. ET.

Children’s Hospital of Philadelphia is thrilled to announce a gift of $5 million from the Wyss Foundation to support innovations that improve the lives of patients with thoracic insufficiency syndrome.

EVŌQ Nano announced its antimicrobial medical device platform has demonstrated effectiveness against the world’s leading pathogens implicated in healthcare-associated infections, which are some of the most common complications of hospital care.

Zynex, Inc. will hold a conference call on Thursday, February 29, 2024 at 4:15 PM Eastern Time to discuss its financial results for the fourth quarter and full year ended December 31, 2023.

Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2023

Resverlogix Corp. (TSX: RVX) (“Resverlogix” or the “Company”) today announced that Shawn Lu has stepped down from the Board of Directors